| Dr Nancy M Mcbride, OD | |
|
6602 Telegraph Rd, Bloomfield Hills, MI 48301-3012 | |
| (248) 419-3500 | |
| (248) 419-3503 |
| Full Name | Dr Nancy M Mcbride |
|---|---|
| Gender | Female |
| Speciality | Optometry |
| Experience | 16 Years |
| Location | 6602 Telegraph Rd, Bloomfield Hills, Michigan |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649426735 | NPI | - | NPPES |
| 1649426735 | Medicaid | MI | |
| 11872180 | Other | NY | CAQH PROVIDER ID |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152WC0802X | Optometrist - Corneal And Contact Management | TUV56007351 (New York) | Secondary |
| 152W00000X | Optometrist | 4901004881 (Michigan) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Southern California Permanente Medical Group | 6002729175 | 7951 |
News Archive
Native American ancestry is associated with a lower asthma risk, but African ancestry is associated with a higher risk, according to the largest-ever study of how genetic variation influences asthma risk in Latinos, in whom both African and Native American ancestry is common. The study, led by UC San Francisco researchers, was published online October 6, 2014 in the Journal of Allergy and Clinical Immunology.
The non-profit International AIDS Vaccine Initiative (IAVI) and biopharmaceutical company CureVac are partnering to accelerate the development of AIDS vaccines, utilizing novel immunogens developed by IAVI and partners, delivered via CureVac's novel messenger RNA (mRNA) technology.
ARCA biopharma, Inc. today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a clinical trial to assess the safety and efficacy of bucindolol in approximately 3,200 patients with chronic heart failure who have the genotype that appears to respond most favorably to bucindolol. Bucindolol is the Company's investigational, pharmacologically unique, beta-blocker and mild vasodilator.
Pharmacyclics LLC today highlighted results from a sub-analysis of the Phase III RESONATE™ (PCYC-1112) trial, which found that previously-treated patients with chronic lymphocytic leukemia (CLL) who adhered to the recommended 420 mg dose of IMBRUVICA® (ibrutinib) experienced improved progression-free survival (PFS; the primary endpoint) as assessed by an Independent Review Committee (IRC), compared to patients who took lower doses or missed doses, regardless of high-risk genetic factors.
Politico: Process is principle in Washington right now, as parliamentary procedure attorneys "clash" over the legal designations and wording of various bills and provisions in the lead up to an attempt to pass health legislation under filibuster-avoiding reconciliation rules. "High drama" and "historic" vote calls are likely, but for now it's the conclusions that come from "behind-the-scenes conversations" that will be center stage.
› Verified 2 days ago
| Provider Name | Southern California Permanente Medical Group |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1770515280 PECOS PAC ID: 6002729175 Enrollment ID: O20031110000678 |
News Archive
Native American ancestry is associated with a lower asthma risk, but African ancestry is associated with a higher risk, according to the largest-ever study of how genetic variation influences asthma risk in Latinos, in whom both African and Native American ancestry is common. The study, led by UC San Francisco researchers, was published online October 6, 2014 in the Journal of Allergy and Clinical Immunology.
The non-profit International AIDS Vaccine Initiative (IAVI) and biopharmaceutical company CureVac are partnering to accelerate the development of AIDS vaccines, utilizing novel immunogens developed by IAVI and partners, delivered via CureVac's novel messenger RNA (mRNA) technology.
ARCA biopharma, Inc. today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a clinical trial to assess the safety and efficacy of bucindolol in approximately 3,200 patients with chronic heart failure who have the genotype that appears to respond most favorably to bucindolol. Bucindolol is the Company's investigational, pharmacologically unique, beta-blocker and mild vasodilator.
Pharmacyclics LLC today highlighted results from a sub-analysis of the Phase III RESONATE™ (PCYC-1112) trial, which found that previously-treated patients with chronic lymphocytic leukemia (CLL) who adhered to the recommended 420 mg dose of IMBRUVICA® (ibrutinib) experienced improved progression-free survival (PFS; the primary endpoint) as assessed by an Independent Review Committee (IRC), compared to patients who took lower doses or missed doses, regardless of high-risk genetic factors.
Politico: Process is principle in Washington right now, as parliamentary procedure attorneys "clash" over the legal designations and wording of various bills and provisions in the lead up to an attempt to pass health legislation under filibuster-avoiding reconciliation rules. "High drama" and "historic" vote calls are likely, but for now it's the conclusions that come from "behind-the-scenes conversations" that will be center stage.
› Verified 2 days ago
| Provider Name | Richard L Silver Od Pc Stacey Sumnerprofessional Visioncare Associates |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1992749287 PECOS PAC ID: 0143381467 Enrollment ID: O20081205000086 |
News Archive
Native American ancestry is associated with a lower asthma risk, but African ancestry is associated with a higher risk, according to the largest-ever study of how genetic variation influences asthma risk in Latinos, in whom both African and Native American ancestry is common. The study, led by UC San Francisco researchers, was published online October 6, 2014 in the Journal of Allergy and Clinical Immunology.
The non-profit International AIDS Vaccine Initiative (IAVI) and biopharmaceutical company CureVac are partnering to accelerate the development of AIDS vaccines, utilizing novel immunogens developed by IAVI and partners, delivered via CureVac's novel messenger RNA (mRNA) technology.
ARCA biopharma, Inc. today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a clinical trial to assess the safety and efficacy of bucindolol in approximately 3,200 patients with chronic heart failure who have the genotype that appears to respond most favorably to bucindolol. Bucindolol is the Company's investigational, pharmacologically unique, beta-blocker and mild vasodilator.
Pharmacyclics LLC today highlighted results from a sub-analysis of the Phase III RESONATE™ (PCYC-1112) trial, which found that previously-treated patients with chronic lymphocytic leukemia (CLL) who adhered to the recommended 420 mg dose of IMBRUVICA® (ibrutinib) experienced improved progression-free survival (PFS; the primary endpoint) as assessed by an Independent Review Committee (IRC), compared to patients who took lower doses or missed doses, regardless of high-risk genetic factors.
Politico: Process is principle in Washington right now, as parliamentary procedure attorneys "clash" over the legal designations and wording of various bills and provisions in the lead up to an attempt to pass health legislation under filibuster-avoiding reconciliation rules. "High drama" and "historic" vote calls are likely, but for now it's the conclusions that come from "behind-the-scenes conversations" that will be center stage.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Nancy M Mcbride, OD 14607 Ventura Blvd, Sherman Oaks, CA 91403-3617 Ph: (818) 789-3311 | Dr Nancy M Mcbride, OD 6602 Telegraph Rd, Bloomfield Hills, MI 48301-3012 Ph: (248) 419-3500 |
News Archive
Native American ancestry is associated with a lower asthma risk, but African ancestry is associated with a higher risk, according to the largest-ever study of how genetic variation influences asthma risk in Latinos, in whom both African and Native American ancestry is common. The study, led by UC San Francisco researchers, was published online October 6, 2014 in the Journal of Allergy and Clinical Immunology.
The non-profit International AIDS Vaccine Initiative (IAVI) and biopharmaceutical company CureVac are partnering to accelerate the development of AIDS vaccines, utilizing novel immunogens developed by IAVI and partners, delivered via CureVac's novel messenger RNA (mRNA) technology.
ARCA biopharma, Inc. today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a clinical trial to assess the safety and efficacy of bucindolol in approximately 3,200 patients with chronic heart failure who have the genotype that appears to respond most favorably to bucindolol. Bucindolol is the Company's investigational, pharmacologically unique, beta-blocker and mild vasodilator.
Pharmacyclics LLC today highlighted results from a sub-analysis of the Phase III RESONATE™ (PCYC-1112) trial, which found that previously-treated patients with chronic lymphocytic leukemia (CLL) who adhered to the recommended 420 mg dose of IMBRUVICA® (ibrutinib) experienced improved progression-free survival (PFS; the primary endpoint) as assessed by an Independent Review Committee (IRC), compared to patients who took lower doses or missed doses, regardless of high-risk genetic factors.
Politico: Process is principle in Washington right now, as parliamentary procedure attorneys "clash" over the legal designations and wording of various bills and provisions in the lead up to an attempt to pass health legislation under filibuster-avoiding reconciliation rules. "High drama" and "historic" vote calls are likely, but for now it's the conclusions that come from "behind-the-scenes conversations" that will be center stage.
› Verified 2 days ago
Mrs. Maryjo Ference, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 2550 S Telegraph Rd Ste 100, Bloomfield Hills, MI 48302 Phone: 248-258-9000 Fax: 248-499-6372 | |
Dr. Paul Charles Feinberg, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 2550 S Telegraph Rd Ste 100, Bloomfield Hills, MI 48302 Phone: 248-258-9000 Fax: 248-499-6372 | |
Dr. Debra Lynn Feinberg, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 2550 S Telegraph Rd, Suite 100, Bloomfield Hills, MI 48302 Phone: 248-258-9000 Fax: 248-499-6372 | |
Eliza Seros, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 4114 W Maple Rd, Bloomfield Hills, MI 48301 Phone: 248-539-4800 | |
Dr. Michael S Weishaus, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 6523 Telegraph Rd, Bloomfield Hills, MI 48301 Phone: 248-593-9955 Fax: 248-593-9966 | |
Vision Specialists Of Michigan Optometrist Medicare: Medicare Enrolled Practice Location: 2550 S Telegraph Rd, Suite 100, Bloomfield Hills, MI 48302 Phone: 248-258-9000 Fax: 248-499-7362 | |
Dr. Kevin Semma, OD Optometrist Medicare: May Accept Medicare Assignments Practice Location: 3683 W Maple Rd, Bloomfield Hills, MI 48301 Phone: 248-246-4466 |